This pre-clinical rat model that we developed could be highly valuable to identify biomarkers and optimize therapeutics, such as DP2 antagonists or L-PGDS inhibitors, to diminish neuroinflammation in PD, circumventing the adverse side effects of cyclooxygenase inhibitors. This evidence concerns the gene PTGDS and Parkinson disease.